PeptidePedia The community reference

Contributions of MolarMassMaeve

User contributions·61 logged edits·page 1 of 1

Contributions by MolarMassMaeve, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 19,822 edits includes activity predating the current log.

  1. 14:30, 26 Jun 2026 (diff | hist) Talk:Trifluoroacetate counterion 885 +171 /* Range of counterion content */ reply
  2. 13:55, 20 Jun 2026 (diff | hist) Talk:Lixisenatide 748 +121 /* Non-attenuating emptying delay */ reply
  3. 13:16, 15 Jun 2026 (diff | hist) Liraglutide 5,967 ±0 add the discontinued indication with its date
  4. 17:04, 14 Jun 2026 (diff | hist) Timeline of incretin therapeutics 4,460 ±0 add the discontinued indication with its date
  5. 23:05, 12 Jun 2026 (diff | hist) Tirzepatide 8,037 ±0 convert the substitution list to a table so the analogues line up
  6. 15:40, 11 Jun 2026 (diff | hist) Talk:Dipeptidyl peptidase-4 885 +183 /* Table row for lixisenatide? */ reply
  7. 08:50, 16 May 2026 (diff | hist) Loss on drying 4,874 ±0 m fix a dangling clause
  8. 13:50, 8 May 2026 (diff | hist) Talk:Amylin 748 +114 /* Insulin-to-amylin ratio */ reply
  9. 14:15, 6 May 2026 (diff | hist) Talk:Glucagon 611 +237 /* Energy-expenditure figure */ reply
  10. 14:58, 30 Apr 2026 (diff | hist) Talk:Liraglutide 748 +153 /* Heptamer self-association */ reply
  11. 02:14, 30 Apr 2026 (diff | hist) Retatrutide 7,421 ±0 give the INN alongside the trade name at first mention
  12. 03:57, 23 Apr 2026 (diff | hist) Dual incretin agonist 5,851 ±0 give the INN alongside the trade name at first mention
  13. 02:43, 19 Apr 2026 (diff | hist) Exenatide 5,754 ±0 m convert the substitution list to a table so the analogues line up
  14. 13:48, 7 Apr 2026 (diff | hist) Talk:Albumin binding half-life extension 611 +226 /* Bound fraction figure */ reply
  15. 14:55, 27 Mar 2026 (diff | hist) Talk:CagriSema 748 +64 /* Why not a unimolecular design? */ reply
  16. 08:19, 9 Mar 2026 (diff | hist) GenScript Peptides 17,125 +642 add the note that self-published material is usable only for what it states about itself
  17. 13:20, 13 Feb 2026 (diff | hist) Talk:Oral semaglutide 611 +102 /* Conditions are part of the product */ reply
  18. 10:20, 12 Feb 2026 (diff | hist) GLP-1 receptor agonist 11,264 ±0 typo
  19. 15:05, 8 Feb 2026 (diff | hist) Talk:Semaglutide 885 +155 /* Oral bioavailability range */ reply
  20. 13:40, 4 Feb 2026 (diff | hist) Talk:GLP-1 receptor agonist 611 +209 /* Half-life table: are the figures comparable? */ reply
  21. 11:05, 16 Jan 2026 (diff | hist) Talk:Exenatide 537 +206 /* Trp-cage description */ new section
  22. 12:40, 14 Jan 2026 (diff | hist) Talk:Peptide 611 +142 /* The fifty-residue boundary */ reply
  23. 20:34, 13 Jan 2026 (diff | hist) Amylin 5,795 ±0 m expand §Physiology
  24. 04:31, 28 Dec 2025 (diff | hist) SUSTAIN trial programme 5,153 ±0 flag the pooled analysis as post hoc
  25. 06:23, 4 Nov 2025 (diff | hist) Vial filling and stoppering 4,833 ±0 add the stopper material, since it affects moisture ingress
  26. 13:19, 4 Oct 2025 (diff | hist) GL Biochem (Shanghai) 16,271 +931 add category for suppliers in China
  27. 10:19, 7 Sep 2025 (diff | hist) Glossary of peptide terminology 4,744 ±0 m split overlong sentence
  28. 23:11, 30 Aug 2025 (diff | hist) Orforglipron 5,373 ±0 add the excipient list from the labelling
  29. 18:26, 14 Aug 2025 (diff | hist) Vial filling and stoppering 4,557 ±0 correct the freezer temperature range given for long-term storage
  30. 18:39, 8 Jul 2025 (diff | hist) Resin cleavage 4,029 ±0 add the figure for the lyophilisation cycle and caption it
  31. 07:35, 24 May 2025 (diff | hist) Chain of custody 4,102 +17 add the citation for the blind-sampling discussion
  32. 06:37, 23 May 2025 (diff | hist) GLP-1 receptor agonist 9,758 ±0 label the animal data as animal data in the sentence, not only in the section heading
  33. 16:40, 14 May 2025 (diff | hist) Talk:Reconstitution calculator 748 +205 /* Should the default vial mass be the gross or net figure? */ reply
  34. 07:44, 8 May 2025 (diff | hist) Tirzepatide 7,773 +1,201 add a hatnote pointing at the analogue with the similar name
  35. 02:51, 30 Apr 2025 (diff | hist) Glossary of peptide terminology 4,611 +40 expand §Clinical and evidence
  36. 19:54, 18 Apr 2025 (diff | hist) Lot traceability 4,002 ±0 m clarify that a certificate is a claim by its issuer
  37. 06:55, 5 Apr 2025 (diff | hist) Aspiration risk under anaesthesia 3,880 ±0 add the discontinuation rate attributable to this effect
  38. 22:08, 21 Mar 2025 (diff | hist) Regulatory status by jurisdiction 3,391 +114 m add the telehealth prescribing point as attributed
  39. 22:14, 17 Mar 2025 (diff | hist) Cagrilintide 3,187 ±0 expand §Material sold under the name
  40. 17:45, 9 Mar 2025 (diff | hist) Dulaglutide 4,161 +171 convert the substitution list to a table so the analogues line up
  41. 11:34, 9 Feb 2025 (diff | hist) Melanotan II 3,358 +655 move a stray full stop inside the reference
  42. 20:38, 28 Jan 2025 (diff | hist) GLP-1 receptor agonist 9,254 +1,083 add the excipient list from the labelling
  43. 17:24, 31 Dec 2024 (diff | hist) Lixisenatide 2,302 ±0 add CAS number, sourced
  44. 16:01, 18 Dec 2024 (diff | hist) Survodutide 3,325 +811 add the structural figure and caption it properly
  45. 01:05, 11 Dec 2024 (diff | hist) Dulaglutide 3,106 ±0 m state plainly that the research-use-only form is not approved for human use
  46. 16:00, 7 Dec 2024 (diff | hist) Methionine oxidation 2,318 +246 expand §Chemistry and promoters
  47. 06:21, 1 Dec 2024 (diff | hist) Liraglutide 3,273 ±0 move the trade-name history out of the lead and into §Regulatory history
  48. 05:37, 9 Nov 2024 (diff | hist) Amylin receptor agonist 2,536 +308 fix a dangling clause
  49. 11:01, 31 Oct 2024 (diff | hist) Vial filling and stoppering 1,319 +1,319 N create article — process stub
  50. 11:02, 1 Oct 2024 (diff | hist) Arcuate nucleus 2,347 +1,076 fix hyphenation per PP:MOS
  51. 09:00, 27 Sep 2024 (diff | hist) Bachem Holding (Suzhou) 1,692 +1,692 N create organisation article per PP:VN
  52. 17:09, 4 Sep 2024 (diff | hist) GLP-1 receptor agonist 5,536 +123 consistent en dashes in ranges
  53. 09:02, 4 Sep 2024 (diff | hist) Talk:Glucagon-like peptide-1 822 +124 /* Residue numbering — (7–36) versus (1–30) */ reply
  54. 11:14, 3 Sep 2024 (diff | hist) Talk:Glucagon-like peptide-1 400 +365 /* Residue numbering — (7–36) versus (1–30) */ new section
  55. 21:44, 30 Aug 2024 (diff | hist) Loss on drying 1,231 ±0 state the titration endpoint and the reagent factor
  56. 05:18, 21 Aug 2024 (diff | hist) Dual incretin agonist 2,556 ±0 expand §Beyond GIP and GLP-1
  57. 04:29, 10 Aug 2024 (diff | hist) Chinese Peptide Company 2,218 ±0 expand §Product range
  58. 16:03, 16 Jul 2024 (diff | hist) Glossary of peptide terminology 1,029 +1,029 N start the list; inclusion criterion in the lead
  59. 15:55, 11 Jul 2024 (diff | hist) Solid-phase peptide synthesis 1,893 ±0 expand §Difficult sequences
  60. 09:00, 26 Jun 2024 (diff | hist) Peptide synthesis 2,036 +2,036 N new article: supply and handling, expansion welcome
  61. 12:42, 15 Jun 2024 (diff | hist) Tirzepatide 1,388 +1,388 N start article on the compound